1h Free Analyst Time
The CANCER immunotherapy market is forecasted to grow by USD 45.5 billion during 2023-2028, accelerating at a CAGR of 8.1% during the forecast period. The report on the CANCER immunotherapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of CANCER, growing awareness among consumers regarding CANCER immunotherapy, and strong R&D pipeline of monoclonal antibodies.
The CANCER immunotherapy market is segmented as below:
By Type
- Monoclonal antibodies
- Check point inhibitors and immunomodulators
- CANCER vaccines
By Application
- Lung CANCER
- Breast CANCER
- Colorectal CANCER
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the CANCER immunotherapy market covers the following areas:
- CANCER immunotherapy market sizing
- CANCER immunotherapy market forecast
- CANCER immunotherapy market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global Cancer immunotherapy market: Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Co., Dendreon Pharmaceuticals LLC, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline PLC, Immunocore Holdings PLC, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Seagen Inc., and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is adoption of various strategies for Cancer immunotherapy market growth."
According to the report, one of the major drivers for this market is the high prevalence of Cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol Myers Squibb Co.
- Dendreon Pharmaceuticals LLC
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Immunocore Holdings Plc
- Inovio Pharmaceuticals Inc.
- Johnson and Johnson Services Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Seagen Inc.
- Takeda Pharmaceutical Co. Ltd.
